ZIM
INSY

Zacks Investment Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Zacks Investment Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,525
Closed -$111K – 683
2017
Q3 		$111K Buy
+12,525
New +$129K ﹤0.01% 564
2014
Q1 		– Sell
-33,930
Closed -$438K – 812
2013
Q4 		$438K Buy
+33,930
New +$471K 0.02% 450

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zacks Investment Management's INSY Position: Q4 2017 in Review

Zacks Investment Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2017, closing a stake of 12,525 shares — an estimated $111K sold.

Zacks Investment Management first reported a position in INSY in Q4 2013 and held it in 2 quarters. The position peaked at $438K in Q4 2013. 112 funds tracked by Wall St. Rank hold INSY as of Q4 2017.

  • Zacks Investment Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Zacks Investment Management sold 12,525 Insys Therapeutics, Inc. shares in Q4 2017, an estimated $111K.
  • Zacks Investment Management first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 2 quarters.
  • Zacks Investment Management's Insys Therapeutics, Inc. position peaked at $438K in Q4 2013.
  • 112 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2017.

Based on Zacks Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.